Sprint Bioscience AB (publ) SPRINT
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold/watch; consider adding only after confirmed new deals or milestones.
The new AI collaboration with Lilly strengthens validation of the company’s methodology but leaves preclinical risk and uncertainty around future milestones unchanged.
Sentiment has strengthened further after the Q3 report and the new AI partnership viewed as a quality stamp.
NEUTRAL is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 12 Nov 2026 — Report shows zero revenue and continued negative result driven by preclinical burn.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (5) — follow the company freeAbout the company
Sprint Bioscience AB (publ) is a Swedish biotech company developing preclinical small-molecule programs, mainly in cancer and tumor metabolism. Its model is to create assets early and out-license/sell them to larger pharma partners. The TREX1 program was sold to Gilead with an upfront payment and potential future milestones.
Bull case
Access to Lilly’s predictive AI models can accelerate out-licensing and raise potential deal values.
Bear case
Preclinical stage and irregular revenues imply continued high burn risk and need for future capital.
Why this signal
The new AI collaboration with Lilly strengthens validation of the company’s methodology but leaves preclinical risk and uncertainty around future milestones unchanged.
Recent news
The Q3 report was published on 11 November showing net sales of 0 MSEK and operating result of –14.7 MSEK. The share rose 7 % after the report. The company presented VRK1 data at ENA 2026 and received Vinnova funding. The next report is the year-end release on 11 February 2027.